{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:32:57Z","timestamp":1775215977872,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.cjca.2023.12.032","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T03:43:05Z","timestamp":1704339785000},"page":"1283-1290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Management Strategies of Anticoagulated Atrial Fibrillation Patients After a Clinically Significant Bleeding Episode"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3501-7414","authenticated-orcid":false,"given":"Philippe","family":"Brouillard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El Hadji","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Bernard","family":"Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounir","family":"Riahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9mi","family":"Kouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannot","family":"Potvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2023.12.032_bib1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s10620-020-06248-9","article-title":"Resuming anticoagulation following hospitalization for gastrointestinal bleeding is associated with reduced thromboembolic events and improved mortality: results from a systematic review and meta-analysis","volume":"66","author":"Tapaskar","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cjca.2023.12.032_bib2","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2023.12.032_bib3","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.09.1085","article-title":"2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways","volume":"70","author":"Tomaselli","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2023.12.032_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ahj.2016.10.003","article-title":"Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)","volume":"183","author":"Osmancik","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2023.12.032_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2023.12.032_bib6","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2023.12.032_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ahj.2017.03.007","article-title":"The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial","volume":"189","author":"Holmes","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2023.12.032_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6704031","article-title":"Left atrial appendage occlusion in high bleeding risk patients","volume":"2019","author":"Merella","year":"2019","journal-title":"J\u00a0Interv Cardiol"},{"key":"10.1016\/j.cjca.2023.12.032_bib9","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2023.12.032_bib10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4244\/EIJV6I2A35","article-title":"PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in nonanticoagulation eligible atrial fibrillation patients: results from the European PLAATO study","volume":"6","author":"Bayard","year":"2010","journal-title":"EuroIntervention"},{"key":"10.1016\/j.cjca.2023.12.032_bib11","article-title":"Two-year outcomes with a next-generation left atrial appendage device: final results of the PINNACLE FLX trial","volume":"12","author":"Doshi","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2023.12.032_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10840-020-00903-x","article-title":"Unprotected discharge: absence of stroke prevention strategies in patients with atrial fibrillation admitted for bleeding","volume":"62","author":"Gorgis","year":"2021","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.cjca.2023.12.032_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/AC.71.2.3141842","article-title":"Left atrial appendage occlusion with the Amplatzer cardiac plug could improve survival and prevent thrombo-embolic and major bleeding events in atrial fibrillation patients with increased bleeding risk","volume":"71","author":"Budts","year":"2016","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.cjca.2023.12.032_bib27","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/bloodadvances.2020003560","article-title":"Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry","volume":"5","author":"Bassand","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.cjca.2023.12.032_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050202","article-title":"CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for Covid-19 in hospitalised adults","volume":"11","author":"Veenith","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.cjca.2023.12.032_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2023.05.022","article-title":"Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation","volume":"264","author":"Kar","year":"2023","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2023.12.032_bib16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(23)00315-0","article-title":"Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials","volume":"22","author":"Al-Shahi Salman","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cjca.2023.12.032_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7326\/0003-4819-155-9-201111010-00004","article-title":"Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable","volume":"155","author":"Connolly","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2023.12.032_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s12471-019-1295-5","article-title":"Left atrial appendage closure in atrial fibrillation patients with prior major bleeding or ineligible for oral anticoagulation","volume":"27","author":"Wintgens","year":"2019","journal-title":"Neth Heart J"},{"key":"10.1016\/j.cjca.2023.12.032_bib19","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1161\/STROKEAHA.120.031707","article-title":"Stroke prevention in older adults: recent advances","volume":"51","author":"Spence","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2023.12.032_bib20","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2023.12.032_bib21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2023.12.032_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cjca.2023.12.032_bib23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/europace\/euu311","article-title":"Nonvitamin K antagonist oral anticoagulants: considerations on once- vs twice-daily regimens and their potential impact on medication adherence","volume":"17","author":"Vrijens","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2023.12.032_bib24","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1161\/01.STR.30.9.1751","article-title":"The North American Symptomatic Carotid Endarterectomy Trial","volume":"30","author":"Ferguson","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2023.12.032_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcin.2020.09.051","article-title":"Clinical outcomes associated with left atrial appendage occlusion versus direct oral anticoagulation in atrial fibrillation","volume":"14","author":"Nielsen-Kudsk","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.cjca.2023.12.032_bib26","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1093\/eurheartj\/ehw048","article-title":"Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation","volume":"37","author":"Panikker","year":"2016","journal-title":"Eur Heart J"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X23020482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X23020482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:49:55Z","timestamp":1775180995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X23020482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0828282X23020482"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2023.12.032","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Management Strategies of Anticoagulated Atrial Fibrillation Patients After a Clinically Significant Bleeding Episode","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2023.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}